Angiotensin-Converting Enzyme-2 (ACE-2) with Interferon-Induced Transmembrane Protein-3 (IFITM-3) Genetic Variants and Interleukin-6 as Severity and Risk Predictors among COVID-19 Egyptian Population

Table 3

Relation between COVID-19 severity and patients’ outcomes among the studied cases of wave 3 and 4.

Outcomes		Mild/moderate		Severe		Critical			Total	0
		No.	%	No.	%	No.		%
		(n = 80)		(n = 150)		(n = 150)
Group I	Recovery	80	100.0	50	33.3	0	0.0		130 (34.2%)	<0.001
	ICU admission	0	0.0	130	86.7	150	100.0		280 (73.7%)	<0.001
	Death (nonsurvivors)	0	0.0	85	56.7	125	83.3		210 (55.3%)	<0.001
	Post-COVID-19 syndrome	64	80.0	30	20.0	0	0.0		94 (24.7%)	<0.001
		(n = 120)		(n = 210)		(n = 190)
Group II	Recovery	120	100.0	112	53.3	39	20.5		271 (52.1%)	<0.001
	ICU admission	0	0.0	56	26.7	190	100.0		246 (47.3%)	<0.001
	Death (nonsurvivors)	0	0.0	98	46.7	132	69.5		230 (44.2%)	<0.001
	Post-COVID-19 syndrome	96	80.0	57	27.1	25	13.2		178 (34.2%)	<0.001
Sig. bet. grps.		, , ,

₀: value for the Chi square test for comparing between mild/moderate and severe and critical in both groups. Sig. bet. grps: value for comparing between group I and group II regarding different outcomes parameters (total) as follows: ₁: value for comparing between group I and group II regarding total recovery. ₂: value for comparing between group I and group II regarding total ICU admission. ₃: value for comparing between group I and group II regarding total death. ₄: value for comparing between group I and group II regarding total post-COVID-19 syndrome. Statistically significant at .